Curefab Receives Investment from High-Tech Gründerfonds and Bayern Kapital

Curefab GmbH, a Munich, Germany-based company that develops innovative tools to enhance early diagnosis and prevention of stroke, has received an investment of undisclosed amount from High-Tech Gründerfonds and Bayern Kapital.
Investors also participating in the financing include First Value AG, Capital Rangers GmbH and optical imaging expert Framos.
The solutions developed by Curefab are designed to support an early diagnosis by indicating risk factors of a stroke. The first prototype was developed for the German Heart Centre Munich in 2008. Supported by the University Hospital Klinikum rechts der Isar in Munich, Germany, the functionality got further enhanced.
The company will now focus on optimizing and expanding the clinical capabilities and application range of its product, as well as building the network of clinical and distribution partners.

Join the discussion